WuXi Biologics (“WuXi Bio”) (2269.HK), a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO), announced its fourth consecutive Platinum Award from The Asset ESG (Environmental, Social, and Governance) Corporate Awards. This recognition highlights the company’s dedication to sustainable practices and its innovative use of green technologies to drive efficiency.
The Asset, a well-known business news and research entity, evaluates companies for its annual ESG Corporate Awards across various metrics such as corporate governance, sustainability financing, supplier codes, energy consumption, greenhouse gas emissions, and waste management. WuXi Biologics was the only healthcare industry company recognized among this year’s winners.
Dr. Chris Chen, CEO and Chairman of the ESG Committee at WuXi Biologics, expressed the company’s pride in receiving the Platinum Award for the fourth year. He emphasized that the award not only celebrates past achievements in sustainability but also motivates continued efforts to lead the biologics CRDMO industry towards a greener and healthier future.
WuXi Biologics aligns its sustainability efforts with the United Nations Sustainable Development Goals and has made significant strides in sustainable development and social responsibility. The company is a signatory to the United Nations Global Compact and the global Science Based Targets initiative (SBTi).
The company’s commitment has earned recognition from leading ESG rating agencies, including an “AAA” rating from MSCI ESG Ratings, a Platinum Medal from EcoVadis, inclusion in the DJSI World Index and Emerging Markets Index, recognition as an Industry and Regional Top-Rated Company by Sustainalytics, placement on the CDP Water Security “A list” and an “A-” rating for CDP Climate Change, as well as listings in the FTSE4Good Index Series and Hang Seng ESG 50 Index.
About WuXi Biologics
WuXi Biologics (2269.HK) is a leading global CRDMO providing end-to-end solutions for biologics discovery, development, and manufacturing. With over 12,000 employees across China, the U.S., Ireland, Germany, and Singapore, the company supports 742 integrated client projects, including 16 in commercial manufacturing as of June 30, 2024.
Committed to ESG responsibilities, WuXi Biologics integrates sustainable practices into its business strategy. The company utilizes advanced biomanufacturing technologies and clean energy and has established an ESG committee to oversee and implement its comprehensive sustainability strategy.
